Picture of Theralase Technologies logo

TLT Theralase Technologies Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m+11.99%
3m+6.98%
6m-19.22%
1yr-5.38%
Volume Change (%)
10d/3m+7.15%
Price vs... (%)
52w High-34.38%
50d MA+18.02%
200d MA-0.81%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value18.57
Price to Tang. Book18.57
Price to Free Cashflown/a
Price to Sales66.11
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-138.75%
Return on Equity-113.1%
Operating Margin-548.62%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Theralase Technologies EPS forecast chart

Profile Summary

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. The Company operates through two divisions, The Anti-Cancer Therapy (ACT) and The Cool Laser Therapy (CLT). ACT division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. CLT division designs, develops, manufactures and markets patented, and its laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerves, muscle and joint conditions. The Company develops products both internally and using the assistance of external resources.

Directors

Last Annual
December 31st, 2021
Last Interim
September 30th, 2022
Incorporated
August 22nd, 1989
Public Since
November 2nd, 2004
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
ca flag iconTSX Venture Exchange
Shares in Issue
215,502,675

TLT Share Price Performance

Upcoming Events for TLT

Q4 2022 Theralase Technologies Inc Earnings Release

Q1 2023 Theralase Technologies Inc Earnings Release

Similar to TLT

Picture of Aurora Spine logo

Aurora Spine

ca flag iconTSX Venture Exchange

Picture of Binovi Technologies logo

Binovi Technologies

ca flag iconTSX Venture Exchange

Picture of CardioComm Solutions logo

CardioComm Solutions

ca flag iconTSX Venture Exchange

Picture of Cloud DX logo

Cloud DX

ca flag iconTSX Venture Exchange

Picture of Enablence Technologies logo

Enablence Technologies

ca flag iconTSX Venture Exchange

FAQ

Or unlock with your email

Or unlock with your email